Aaron Guo
YOU?
Author Swipe
View article: The Prognostic Value of Lymph Node Downstaging Following Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
The Prognostic Value of Lymph Node Downstaging Following Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer Open
Background: The use of immune checkpoint inhibitors (ICI) and other targeted molecular agents for non-small cell lung cancer (NSCLC) has led to unprecedented rates of major pathologic response and improvements in overall survival. The aim …
View article: Perivascular Epithelioid Cell Tumor of the Lung With a Novel <i>YAP1::TFE3</i> Fusion
Perivascular Epithelioid Cell Tumor of the Lung With a Novel <i>YAP1::TFE3</i> Fusion Open
Perivascular epithelioid cell tumor (PEComa) belongs to a family of rare mesenchymal neoplasms that share characteristic morphologic, immunohistochemical and molecular findings. In this report, we provide a detailed clinicopathological cha…
View article: HeartMate 3 Implantation Through Left Atrial e-PTFE Conduit for Restrictive Cardiomyopathy
HeartMate 3 Implantation Through Left Atrial e-PTFE Conduit for Restrictive Cardiomyopathy Open
Restrictive or hypertrophic cardiomyopathy presents a challenge to left ventricular assist device placement because of the small left ventricle cavity. Cases have described inflow cannulation of the HeartWare HVAD by expanded polytetrafluo…
View article: The Impact of Pazopanib on the Cardiovascular System
The Impact of Pazopanib on the Cardiovascular System Open
Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endot…
View article: Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model
Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model Open
Our findings in mice clearly demonstrate that treatment with pazopanib leads to a significant elevation in blood pressure after 2 weeks of dosing and this persists for the duration of dosing. The continued development of the cardio-oncolog…